3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Gastrointestinal
1
Conditions
Mesothelioma
2
Solid Tumors
1
Solid Tumor, Adult
1
Solid Tumor
1
Retinoblastoma
1
Pseudomyxoma Peritonei
1
Mesothelioma, Malignant
1
Lung Diseases
1
Hematopoietic and Lymphatic System Neoplasm
1
Colonic Neoplasms
1
Childhood Solid Tumor
1
Carcinoma, Ovarian Epithelial
1
Appendiceal Neoplasms
1
Advanced Cancers
1
Advanced Cancer
1
Interventions
Cisplatin
57
Pemetrexed
46
pembrolizumab
18
Nivolumab
15
Carboplatin
15
Gemcitabine
14
Cyclophosphamide
13
Radiotherapy
10
Drug Therapy
9
atezolizumab
8
Platinum
7
Ipilimumab
7
Doxorubicin
7
durvalumab
6
1,2-diaminocyclohexaneplatinum II citrate
6
tremelimumab
5
sodium thiosulfate
5
Vinorelbine
5
Radiotherapy, Intensity-Modulated
5
Interleukin-2
5
Chemotherapy, Adjuvant
5
Cerebral Decortication
5
sargramostim
4
fludarabine
4
defactinib
4
aldesleukin
4
tumor necrosis factor-alpha, CNGRC fusion protein, human
3
cediranib
3
Photochemotherapy
3
Neoadjuvant Therapy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma, Malignant
×
Surveys and Questionnaires
×
Other solid neoplasm
×
Clear all
NCT01126346
2018-07-03
HOPE
Wake Forest University Health Sciences
Phase NA
Completed
10 enrolled